Pharma Perspectives Panel Discussion: Successfully Engaging with Large Pharma Companies to Secure Future Partnerships for GBM Therapeutic Development

• Identifying specific data packages, preclinical models and clinical milestones that will make a GBM asset attractive for a partnership, beyond scientific novelty
• Strategies for pitching, due diligence considerations and building collaborative relationships to effectively engage with big pharma business development teams to secure a deal
• Insights into creative deal terms, IP considerations and defining clear roles and responsibilities to ensure both partners are aligned on the path to clinical and commercial success

Speakers:

Ranjit bindra

professor

Yale Univerisity

Carla Bauer

Director, Search & Evaluation, Business Development & Licensing

Merck & Co